Monday, December 23, 2024

Amgen and Biolabs LA at the Lundquist Institute Announce That Karma Biotechnologies Will Receive the Second Amgen Golden Ticket

Amgen and BioLabs LA at the Lundquist Institute announced that Karma Biotechnologies has been awarded the second Amgen Golden Ticket in Southern California. Karma Biotechnologies will receive one year of lab space at BioLabs LA at the Lundquist Institute (TLI) as well as additional facility benefits and connections to Amgen’s scientific and business leaders.

Also Read: Nuvalent Announces First Patient Dosed in ARROS-1 Phase 1/2 Clinical Trial of NVL-520, its Novel ROS1-selective Inhibitor

The Amgen Golden Ticket winner was chosen by an internal team of Amgen scientific leaders at a virtual pitch event. Five finalists pitched their business plans before Amgen’s internal committee that evaluated the strength and novelty of their scientific rationale, subject matter expertise and business plan viability. This is the second of three Amgen Golden Tickets to be awarded through 2023 to help accelerate life science start-ups in Southern California.

Amgen supports life science start-ups through Golden Ticket awards and affiliated engagement in other Biotech Innovative hubs, including San Francisco, Boston and Toronto. Karma Biotechnologies is the 26th Golden Ticket winner since program inception in 2014.

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World’s Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron’s.

Subscribe Now

    Hot Topics